Genetix Pharmaceuticals has launched its clinical program to treat Adrenoleukodystrophy (ALD). It is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier
Boston Scientific has reached an agreement, in principle, with the US Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The alleged
The FDA has approved Gloucester Pharmaceuticals’ Istodax (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL), in patients who have received at least one prior systemic therapy. Istodax
Helix BioPharma has completed patient enrollment in its phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW), with the required 120th patient randomized
Abraxis BioScience’s chemotherapy agent, ABRAXANE for injectable suspension, has received orphan drug designation from the Office of Orphan Products Development of the FDA. It is intended for the
Novartis has received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura. Novartis said that it will continue to pursue
Daiichi Sankyo has launched a new Phase III trial of its anti-influenza agent, CS-8958. The company’s goal is to gain an influenza prevention indication in Japan. The trial
Phase Forward has entered into a multi-year agreement with Quotient Clinical, a strategic business unit of Quotient Bioresearch (Quotient). Quotient is implementing Phase Forward’s InForm Global Trial Management
NeuroVive Pharmaceutical has completed the clinical phase of its study investigating tolerability and pharmacokinetics of the cremophor-free cyclosporine formula NeuroSTAT. The study is entitled: “A study to compare
According to the CMS Industry Report 2009, Chemical Management Services (CMS) providers reported 30% revenue growth per year between 2006-2008 by helping their customers significantly reduce their chemical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.